Asia Pacific Cardiac Biomarkers Market Size & Outlook
Asia Pacific cardiac biomarkers market, 2018-2030 (US$M)
Asia Pacific cardiac biomarkers market highlights
- The Asia Pacific cardiac biomarkers market generated a revenue of USD 5,157.0 million in 2024.
- The market is expected to grow at a CAGR of 16% from 2025 to 2030.
- In terms of segment, troponin was the largest revenue generating type in 2024.
- Troponin is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 5,157.0 million |
| Market revenue in 2030 | USD 12,541.4 million |
| Growth rate | 16% (CAGR from 2025 to 2030) |
| Largest segment | Troponin |
| Fastest growing segment | Troponin |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Troponin, CK-MB, Myoglobin, BNP and NT-proBNP |
| Key market players worldwide | Abbott Laboratories, QuidelOrtho Corp, Siemens Healthineers AG ADR, Roche Holding AG ADR, Danaher Corp, BioMerieux SA, Bio-Rad Laboratories Inc, Randox, Creative Diagnostics, Life Diagnostics |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 22.2% of the global cardiac biomarkers market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 12,541.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cardiac Biomarkers Market Scope
Cardiac Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific cardiac biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac biomarkers market will help companies and investors design strategic landscapes.
Troponin was the largest segment with a revenue share of 41.54% in 2024. Horizon Databook has segmented the Asia Pacific cardiac biomarkers market based on troponin, ck-mb, myoglobin, bnp and nt-probnp covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to be the fastest growing segment in the cardiac biomarkers vertical. This growth is attributed to numerous factors. The population in the Asia Pacific region was 4.4 billion, of which China and India accounted for 1.3 billion and 1.2 billion, respectively, in 2014.
The high population in the countries of China and India are one of the major drivers expected to propel the growth of the cardiac biomarkers market. Secondly, according to the reports published by the U.S. National Library of Medicine and National Institutes of Health, the epidemiology of CVDs in the Asia Pacific region is very high, which accounts for nearly half the number of CVD deaths in the world.
These looming fatalities related to CVDs continue to persist in countries such as China and India. According to a recent article published by the Journal of Preventive Cardiology, India has a high prevalence of CVDs in comparison to other developing countries.
Reasons to subscribe to Asia Pacific cardiac biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific cardiac biomarkers market databook
-
Our clientele includes a mix of cardiac biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cardiac biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cardiac biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific cardiac biomarker market size, by country, 2018-2030 (US$M)
Asia Pacific Cardiac Biomarkers Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
